Using an ex vivo clinical approach, we characterized the bioavailability of the blend and demonstrated that the circulating metabolites resulting from TOTUM-854 ingestion in humans were able to maintain endothelial cell function in a lipotoxic environment by (1) inhibiting ACE-1 activity, (2) limiting oxidative stress, (3) preventing the release of IL-1β, and (4) reducing the expression of MCP-1 and VCAM-1, which are both involved in inflammation and the recruitment of immune cells that drive endothelial dysfunction onset. The gene discussed is CCL2; the disease is endothelial dysfunction.